Safety, Tolerability, and Activity Study of ISIS SOD1Rx to Treat Familial Amyotrophic Lateral Sclerosis (ALS) Caused by SOD1 Gene Mutations
Summary
The lay summary the sponsor registered on ClinicalTrials.gov.
Investigators
The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.
- Timothy Miller, MD, PhD
Washington University School of Medicine
Study Chair
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
4 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- Johns Hopkins University
Baltimore, Maryland, United States
- Massachusetts General Hospital-East, Neurology Clinical Trials Unit
Charlestown, Massachusetts, United States
- Washington University School of Medicine
St Louis, Missouri, United States
- Methodist Neurological Institute
Houston, Texas, United States
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.
Registration & key dates
Registry attributes as recorded on the ClinicalTrials.gov study record.
- Start
- 31 Jan 2010
- Primary completion
- 31 Dec 2011
- Completion
- 31 Jan 2012
- Last update posted
- 13 Apr 2012
- Registered enrollment
- 33
- Registry id
- NCT01041222
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 24 Aug 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.